Literature DB >> 12845629

Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.

Jan J Koornstra1, Jan H Kleibeuker, Caroline M M van Geelen, Fleur E M Rijcken, Harry Hollema, Elisabeth G E de Vries, Steven de Jong.   

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in tumour cell lines. Four membrane-bound receptors for TRAIL have been identified, two apoptosis-mediating receptors, DR4 and DR5, and two apoptosis-inhibiting receptors, DcR1 and DcR2. The aim of this study was to examine the role of TRAIL and its receptors in colorectal cancer development. The immunohistochemical expression and localization of TRAIL and its receptors were investigated in normal mucosa (n=10), adenomas (n=19), and carcinomas (n=21). Correlations between the expression of TRAIL and its receptors and the degree of apoptosis (assessed by M30 expression) and histopathological characteristics were explored. TRAIL and its receptors were expressed in normal mucosal epithelium. Expression of the receptors was seen in adenomas and carcinomas. TRAIL expression was lost in a subset of colorectal tumours, more frequently in carcinomas than in adenomas (p<0.05). DR4 and DR5 staining was stronger in neoplastic cells than in normal cells and was accompanied by a higher degree of apoptosis. No differences were found between tumour and normal cells regarding DcR1 and DcR2 expression. No correlations were found between TRAIL or TRAIL receptor expression and histopathological characteristics. In conclusion, marked changes were seen in the course of the adenoma-carcinoma sequence with respect to the expression of TRAIL and TRAIL receptors DR4 and DR5. The stronger expression of DR4 and DR5 in neoplastic cells than in normal cells, together with a higher degree of apoptosis, suggests a possible functional role for these receptors in apoptosis induction in neoplastic colorectal cells. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845629     DOI: 10.1002/path.1364

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  34 in total

1.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

2.  TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis.

Authors:  Jieqing Zhu; Longfei Chen; Juan Shi; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

3.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

4.  Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

Authors:  Donal P McLornan; Helen L Barrett; Robert Cummins; Ultan McDermott; Cliona McDowell; Susie J Conlon; Victoria M Coyle; Sandra Van Schaeybroeck; Richard Wilson; Elaine W Kay; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

5.  Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Authors:  Patsy G Oliver; Albert F LoBuglio; Kurt R Zinn; Hyunki Kim; Li Nan; Tong Zhou; Wenquan Wang; Donald J Buchsbaum
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 7.  Transformation, translation and TRAIL: an unexpected intersection.

Authors:  Shai White-Gilbertson; Semyon Rubinchik; Christina Voelkel-Johnson
Journal:  Cytokine Growth Factor Rev       Date:  2008-04       Impact factor: 7.638

8.  Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma.

Authors:  Kyung Hwa Lee; Sang Woo Lim; Ho Gun Kim; Dong Yi Kim; Seong Yeob Ryu; Jae Kyun Joo; Jung Chul Kim; Jae Hyuk Lee
Journal:  Langenbecks Arch Surg       Date:  2009-04-07       Impact factor: 3.445

Review 9.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Authors:  Andrew Thorburn; Kian Behbakht; Heide Ford
Journal:  Drug Resist Updat       Date:  2008-04-18       Impact factor: 18.500

10.  Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

Authors:  Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Journal:  J Mol Med (Berl)       Date:  2009-08-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.